CliffBio
biologic

Menveo

Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine

Loss of exclusivityOctober 2034projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline Biologicals

Drug detail

Brand nameMenveo
Active ingredientMeningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalOctober 2022
Marketing statusRx

More from GlaxoSmithKline Biologicals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Menveo patent cliff — loss of exclusivity October 2034 | CliffBio